Heron Therapeutics (HRTX) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Heron Therapeutics (HRTX) over the last 11 years, with Q4 2024 value amounting to $17.8 million.
- Heron Therapeutics' Accumulated Depreciation & Amortization rose 480.97% to $17.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $17.8 million, marking a year-over-year increase of 480.97%. This contributed to the annual value of $17.8 million for FY2024, which is 480.97% up from last year.
- Latest data reveals that Heron Therapeutics reported Accumulated Depreciation & Amortization of $17.8 million as of Q4 2024, which was up 480.97% from $17.0 million recorded in Q4 2023.
- Over the past 5 years, Heron Therapeutics' Accumulated Depreciation & Amortization peaked at $17.8 million during Q4 2024, and registered a low of $10.9 million during Q4 2020.
- Over the past 5 years, Heron Therapeutics' median Accumulated Depreciation & Amortization value was $14.3 million (recorded in 2022), while the average stood at $14.7 million.
- Per our database at Business Quant, Heron Therapeutics' Accumulated Depreciation & Amortization surged by 3547.66% in 2020 and then surged by 480.97% in 2024.
- Over the past 5 years, Heron Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $10.9 million in 2020, then increased by 21.81% to $13.2 million in 2021, then grew by 7.93% to $14.3 million in 2022, then rose by 19.14% to $17.0 million in 2023, then increased by 4.81% to $17.8 million in 2024.
- Its last three reported values are $17.8 million in Q4 2024, $17.0 million for Q4 2023, and $14.3 million during Q4 2022.